C
Chen Wang
Researcher at Mayo Clinic
Publications - 198
Citations - 15466
Chen Wang is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Medicine & Serous fluid. The author has an hindex of 33, co-authored 159 publications receiving 11490 citations. Previous affiliations of Chen Wang include Shanghai Jiao Tong University & University of Science and Technology of China.
Papers
More filters
Proceedings ArticleDOI
S1-8: Molecular Signaling Distinguishes Early ER Positive Breast Cancer Recurrences Despite Adjuvant Tamoxifen.
Minetta C. Liu,JM Dixon,Jason Xuan,Rebecca B. Riggins,Li Chen,Chen Wang,Y Cho,Yuelin Zhu,Lu Jin,Alan Zwart,Mingyue Wang,Uwe Klimach,YJ Wang,Lorna Renshaw,Alexey Larionov,William R. Miller,Robert Clarke +16 more
TL;DR: Significant molecular differences exist between ER+ BC that recur early vs. much later despite adjuvant TAM, and exploiting these differences will improve the understanding of involved signaling pathways, allow for the reliable prediction of early treatment failure, and guide use of novel therapeutics specifically directed at preventing E vs L recurrences on endocrine therapy.
Journal ArticleDOI
An innovative approach to predict technology evolution for the desoldering of printed circuit boards: A perspective from China and America
TL;DR: An innovative approach integrating Theory of Inventive Problem Solving (TRIZ) evolution theory and technology maturity mapping system is proposed to forecast the evolution trends of desoldering technology of waste printed circuit boards, predicting the law of energy conductivity and increasing the degree of idealisation.
Journal ArticleDOI
Modeling cancer clinical trials using HL7 FHIR to support downstream applications: A case study with colorectal cancer data.
Nansu Zong,Daniel J. Stone,Deepak Sharma,Andrew Wen,Chen Wang,Yue Yu,Ming Huang,Sijia Liu,Hongfang Liu,Qian Shi,Guoqian Jiang +10 more
TL;DR: CRFs can be considered as a proxy for representing information needs for their respective cancer types and can serve as a valuable resource for expanding existing standards to ensure they can comprehensively represent relevant clinical data without loss of granularity.
Journal ArticleDOI
Gene signature model for breast cancer risk prediction for women with sclerosing adenosis
Amy C. Degnim,Aziza Nassar,Melody Stallings-Mann,S. Keith Anderson,Ann L. Oberg,Robert A. Vierkant,Ryan D. Frank,Chen Wang,Stacey J. Winham,Marlene H. Frost,Lynn C. Hartmann,Daniel W. Visscher,Derek C. Radisky +12 more
TL;DR: The results provide the first demonstration that benign breast tissue contains transcriptional alterations that indicate risk of breast cancer development, demonstrating that essential precursor biomarkers of malignancy are present many years prior to cancer development.
Journal ArticleDOI
Frequent POLE-driven hypermutation in ovarian endometrioid cancer revealed by mutational signatures in RNA sequencing.
Jaime I. Davila,Jaime I. Davila,Pritha Chanana,Vivekananda Sarangi,Zachary C. Fogarty,S. John Weroha,Ruifeng Guo,Ellen L. Goode,Yajue Huang,Chen Wang +9 more
TL;DR: The largest cohort of RNA-seq from endometrioid OC to date, identified six hypermutated samples likely driven by POLE, which suggests the clinical need to screen for POLE driver mutations in endometioid OC, which can guide enrollment in immunotherapy clinical trials.